WEN-CHI YANGJIN-YUAN SHIHCHAO-CHI HOFENG-MING HSU2021-07-022021-07-0220180167-8140https://www.scopus.com/inward/record.uri?eid=2-s2.0-85039043484&doi=10.1016%2fj.radonc.2017.12.001&partnerID=40&md5=3651238b92d84182549663f737252726https://scholars.lib.ntu.edu.tw/handle/123456789/567699[SDGs]SDG3B Raf kinase; crizotinib; dabrafenib; epidermal growth factor receptor; epidermal growth factor receptor 2; brain metastasis; cancer radiotherapy; cancer survival; clinical outcome; Editorial; gene mutation; gene rearrangement; human; molecularly targeted therapy; oncogene; oncogene K ras; overall survival; priority journal; progression free survival; radiosensitivity; small cell lung cancer; stereotactic radiosurgery; treatment responseletter10.1016/j.radonc.2017.12.001292877372-s2.0-85039043484